You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFerric Carboxymaltose
Accession NumberDB08917
TypeSmall Molecule
GroupsApproved
DescriptionFerric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
Structure
Thumb
Synonyms
Iron Carboxymaltose
Iron Dextri-Maltose
VIT 45
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Injectaferinjection, solution50 mg/mLintravenousAmerican Regent, Inc.2013-08-12Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6897GXD6OE
CAS number9007-72-1
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFerric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.
PharmacodynamicsWhen measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red cell uptake ranged from 61% to 84%.
Mechanism of actionFerric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that release iron.
Related Articles
AbsorptionWhen a single dose of 100 to 1000 mg of iron was given to iron deficient patients, the maximum serum concentration (Cmax) was 37 μg/mL to 333 μg/mL. These levels were obtained 15 minutes to 1.21 hours post dose (Tmax).
Volume of distribution

3 L

Protein bindingNot Available
MetabolismNot Available
Route of eliminationRenal elimination of iron was negligible.
Half life7 to 12 hours.
ClearanceNot Available
ToxicityThe most common adverse reactions (>2%) are nausea, hypertension, flushing, hypophosphatemia, and dizziness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionintravenous50 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7612109 No2004-02-052024-02-05Us
US7754702 No2007-02-132027-02-13Us
US8895612 No2007-01-082027-01-08Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 20:04.04
PDB EntriesNot Available
FDA labelDownload (269 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Ferric Carboxymaltose.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Ferric Carboxymaltose.
DimercaprolDimercaprol may increase the nephrotoxic activities of Ferric Carboxymaltose.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric Carboxymaltose.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Ferric Carboxymaltose.
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Ferric Carboxymaltose.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Ferric Carboxymaltose.
Lipoic AcidFerric Carboxymaltose can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Ferric Carboxymaltose.
PenicillamineFerric Carboxymaltose can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TriethylenetetramineThe serum concentration of Ferric Carboxymaltose can be decreased when it is combined with Triethylenetetramine.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2013 23:33 / Updated on September 25, 2016 02:16